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Exogenous administration of vascular endothelial growth factor prior to
human respiratory syncytial virus a2 infection reduces pulmonary
pathology in neonatal lambs and alters epithelial innate immune responses
Abstract
Human respiratory syncytial virus (RSV) affects thousands of children every year. Vascular endothelial
growth factor (VEGF) is a regulator of vasculogenesis, pulmonary maturation, and immunity. In order to test
the extent to which VEGF may alter RSV infection, 4 groups of lambs received either human recombinant
VEGF (rhVEGF) or phosphate-buffered saline (PBS) pretreatment followed by inoculation with human RSV
strain A2 or sterile medium. Lambs in each group were sacrificed at 2, 4, and 6 days post infection. Expression
of surfactant protein-A (SP-A), surfactant protein-D (SP-D), sheep β-defensin-1 (SBD-1), tumor necrosis
factor α (TNFα), interleukin (IL)-6, IL-8, interferon β, and endogenous VEGF were measured to determine
effect of rhVEGF pretreatment. RSV lambs pretreated with rhVEGF had reduced viral mRNA and decreased
pulmonary pathology at day 6. Pretreatment with rhVEGF increased mRNA expression of SP-A, SBD-1, and
TNFα, with alteration of expression in RSV lambs. Endogenous VEGF mRNA levels were increased at day 2
regardless of pretreatment. Pretreatment with rhVEGF increased pulmonary cellular proliferation in RSV
lambs at day 4 post infection. Overall, these results suggest that pretreatment with rhVEGF protein may have
therapeutic potential to decrease RSV viral load, decrease pulmonary lesion severity, and alter both epithelial
innate immune responses and epithelial cell proliferation.
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Abstract
Human respiratory syncytial virus (RSV) affects thousands of children every year. Vascular
endothelial growth factor (VEGF) is a regulator of vasculogenesis, pulmonary maturation, and
immunity. In order to test the extent to which VEGF may alter RSV infection, 4 groups of lambs
received either human recombinant VEGF (rhVEGF) or phosphate-buffered saline (PBS)
pretreatment followed by inoculation with human RSV strain A2 or sterile medium. Lambs in
each group were sacrificed at 2, 4, and 6 days post infection. Expression of surfactant protein-A
(SP-A), surfactant protein-D (SP-D), sheep β-defensin-1 (SBD-1), tumor necrosis factor α
(TNFα), interleukin (IL)-6, IL-8, interferon β, and endogenous VEGF were measured to determine
effect of rhVEGF pretreatment. RSV lambs pretreated with rhVEGF had reduced viral mRNA and
decreased pulmonary pathology at day 6. Pretreatment with rhVEGF increased mRNA expression
of SP-A, SBD-1, and TNFα, with alteration of expression in RSV lambs. Endogenous VEGF
mRNA levels were increased at day 2 regardless of pretreatment. Pretreatment with rhVEGF
increased pulmonary cellular proliferation in RSV lambs at day 4 post infection. Overall, these
results suggest that pretreatment with rhVEGF protein may have therapeutic potential to decrease
RSV viral load, decrease pulmonary lesion severity, and alter both epithelial innate immune
responses and epithelial cell proliferation.
Keywords
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Respiratory syncytial virus (RSV) is a pneumovirus in the paramyxoviridae family. RSV is
the most significant cause of acute respiratory tract infection in infants [1]. Thousands of
children are affected by RSV every year, with more severe infection in premature and
respiratory compromised infants [2]. There are few effective treatments for RSV; however,
prophylactic administration of an anti-RSV monoclonal antibody has been effective in
decreasing disease in high-risk infants and children [3]. Until an effective vaccine is
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developed, there is still a great need to find and develop other therapeutic targets to decrease
virus-induced pathology.
Vascular endothelial growth factor (VEGF) is a potent endothelial cell growth factor,
mitogen, and survival factor [4] that has well-known vascular permeability functions that are
important in inflammation and wound healing [5, 6]. VEGF has numerous nonendothelial
functions and is highly expressed in tissues with specialized epithelial barriers, such as the
lung and kidney [7]. In the lung, VEGF is expressed by alveolar type II cells, bronchiolar
epithelial cells [8], and alveolar macrophages [9, 10]. Given the high pulmonary expression,
there is a vast array of research examining altered levels of VEGF in pulmonary homeostasis
and disease.
VEGF-A is a member of the vascular endothelial growth factor family, which also includes
VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placenta growth factor. The gene encoding
VEGF-A is comprised of 8 exons that are alternatively spliced to yield multiple protein
isoforms with varying activities [6, 10]. The isoforms include VEGF121, VEGF145,
VEGF165, VEGF189, and VEGF206. VEGF165 is the predominant isoform and the most
potent [11]. VEGF121 is freely diffusible, whereas VEGF189 and VEGF206 are bound within
the extracellular matrix. VEGF165 is both diffusible and sequestered to the cell surface and
extracellular matrix via its heparin binding moieties.
During pulmonary development adequate levels of VEGF are critical for the proper
formation of pulmonary capillaries. Inactivation of the VEGF-A gene in lung epithelia of
mice embryos results in almost complete absence of pulmonary capillaries with abnormal
alveolar septae formation [12]. Treatment of rats with a VEGF receptor blocker (SU5416)
leads to alveolar apoptosis and subsequent emphysema, demonstrating that VEGF is
necessary for the maintenance of alveolar structure [13]. There is controversy and
conflicting data concerning the role of altered VEGF expression in acute and chronic
pulmonary disease. Previous in vitro studies show that RSV induces increased VEGF
expression [14, 15]. This does not appear to be the case for all respiratory viruses as
infection with rhinovirus does not result in an increase in VEGF expression [16].
We previously demonstrated that lambs inoculated with human RSV, strain A2, developed
lesions similar to those of human neonates [17, 18], with peak infection observed at 6 days
post infection [18]. Ovine lung is a good pulmonary model, as the pulmonary structure and
development are similar to human lung and sheep are susceptible to human strains of RSV.
In addition, the respiratory epithelia of the airways, bronchioles, and alveoli in sheep are
composed of similar ratios in cell types as humans, whereas mice have large populations of
Clara cells in the bronchiolar airway [19, 20]. Sheep have similar bronchiolar glands, airway
capillaries, and cough reflexes as humans [21].
In this study, we hypothesized that pretreatment with recombinant human (rh) VEGF prior
to infection with human RSV, strain A2, would increase expression of important epithelial
innate immune genes and thereby increase viral clearance and reduce pulmonary pathology.
Additionally, we proposed that transcription of endogenous VEGF and VEGF receptors in
the lung would be altered by RSV infection.
METHODS
Experimental procedure
Animal use and experimental procedures were approved by Iowa State University’s Animal
Care and Use Committee. Neonatal lambs (2 to 3 days of age) were randomly assigned to 3
main groups: 2-day (n = 16), 4-day (n = 16), and 6-day (n = 24), based on length of infection
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period. Within each of these groups, animals were then assigned to treatment groups (Table
1). All lambs were pretreated with recombinant human VEGF165 (30 μg/kg) (Invitrogen or
GenWay Biotech) or phosphate-buffered saline (PBS). Animals in the day 2 and 4 groups
were treated via intrabronchial administration while those in the day 6 group were treated
via intratracheal administration. Thirty minutes following pretreatment, animals were
inoculated with human RSV virus (10 mL, 3 × 106 plaque-forming units [PFU]/mL) or cell
growth medium (10 mL). RSV (A2 strain) was propagated in HEp-2 cells (American Type
Culture Collection [ATCC], Manassas, VA). The inoculum was a cleared supernatant from
infected cells that underwent a centrifugation step to remove cellular debris. The virus was
tittered via plaque assay on VERO cells according to standard protocols. Prior to and
following inoculation, lambs were administered daily antibiotics (ceftiofur, 2.2 mg/kg,
intramuscular) to prevent bacterial pulmonary complications. Lambs were monitored daily
for clinical signs of respiratory disease (coughing and wheezing) and temperatures were
recorded. Animals were sacrificed by sodium pentobarbital on days 2, 4, and 6 post
inoculation.
Tissue samples were taken at the same location of the right and left cranial, middle, caudal
lobes, and accessory lobe. Samples were placed in cassettes and then in 10% neutral-
buffered formalin in preparation for histologic analysis. Additional lung samples were taken
from these sites and snap-frozen on dry ice for real-time quantitative polymerase chain
reaction (PCR).
Immunohistochemical analysis
Immunohistochemical staining was performed for RSV antigen (1:50, overnight incubation,
goat anti-human polyclonal antibody; BioDesign/Meridian) and for proliferating cells using
an antibody against the Ki-67 protein (1:100, overnight incubation, mouse anti-human
monoclonal antibody; Dako). Briefly, paraffin-embedded lung sections were cut at 5 μm
thickness onto positively charged slides. Slides were incubated at 58°C for 25 minutes,
deparaffinized in xylene, rehydrated in graded ethanol washes, and washed in phosphate-
buffered saline (PBS). For RSV immunohistochemistry, tissue sections were treated with
Pronase E (Protease Type XIV from Streptomyces griseus; Sigma) for 12 minutes at 37°C.
Nonspecific binding was blocked by incubation in 20% normal swine. For Ki-67
immunohistochemistry, tissue sections were boiled for 15 minutes in 0.01 M citric acid (pH
6.0). Following overnight incubation with the primary antibodies, the slides were rinsed and
then incubated with an appropriate biotinylated secondary antibody at a concentration of
1:300. A peroxidase block with 3% peroxide was followed by incubation with peroxidase-
conjugated streptavidin (BioGenex) for 45 minutes. After 3 PBS washes, the color was
developed with Nova Red. The slides were then counterstained with Harris’ hematoxylin,
dehydrated, and cover-slipped.
Histology scoring
Histologic lesion scores were determined from 2 lung sections per RSV-infected lamb in
each pretreatment group (e.g., VEGF versus PBS). Sections were scored by a pathologist
blinded to the study groups to determine total alveolar consolidation and cellular infiltration.
Alveolar consolidation was defined by reduced expansion of alveolar lumen due to alveolar
septal infiltration of neutrophils, lymphocytes, plasma cells, and type II cell hypertrophy
along with intralumenal accumulation of neutrophils, macrophages, and small amounts of
cell debris. A total of 5 20× fields were examined per lung section and alveolar
consolidation was scored as: 0 = no consolidation; 1 = 1–30% consolidation; 2 = 30–50%
consolidation; 3 = 60–80% consolidation; 4 = >80% consolidation. Values were averaged
per section and converted to a percentage value.
Olivier et al. Page 3
Exp Lung Res. Author manuscript; available in PMC 2011 September 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Two lung sections from all animals were examined to determine the number of Ki-67
immunoreactive cells. A total of 10 20× fields were examined per lung section and values
were averaged.
One-step real-time qPCR
Total RNA was isolated from whole lung tissue (affected areas as determined grossly or by
immunohistochemistry for RSV antigen) via Trizol according to manufacturer’s guidelines
(Invitrogen, Carlsbad, CA). Following RNA isolation, the pellets were resuspended in 0.1
mM EDTA, pH 6.75, and heated at 65°C for 5 minutes. Samples were diluted 1:50 and
absorbance readings at 260 and 280 nm were measured to determine RNA concentration and
purity. RNA samples were DNase treated (TURBO DNase; Ambion) and diluted 1:10 with
nuclease-free water and RNAseOUT (Invitrogen) for one-step real-time quantitative PCR
(qPCR). Reactions were carried out using SuperScript III Platinum One-Step quantitative
reverse transcriptase (RT)-PCR system with ROX kit (Invitrogen). A test plate was run
using a mixture of RNA samples serially diluted to determine the optimal dilution range for
each target. Primer and probe sequences used in our laboratory have been previously
described [18, 22, 23] (Table 2). The ovine VEGF primers and probe detected ovine VEGF
isoforms (VEGF120, VEGF164, VEGF187). Following determination of the optimal dilution
range for each target, samples and standards were run in duplicate [24]. Each target gene
amplification was converted to a relative quantity using a target-specific standard curve and
then normalized to the reference gene, ubiquitin, and OvRPS15 [25].
Statistical analysis
Statistical analyses were performed with commercially available statistics software
(GraphPad Prism, GraphPad Software). Data were analyzed for normal distribution and log
transformed when necessary. Comparisons were done using 1-way analysis of variance
(ANOVA) followed by Tukey’s posttest analysis. Histologic lesion score data were
analyzed using a Student t test. Data are represented as means (SEM). P < .05 was
considered to be significant unless otherwise noted.
RESULTS
Clinical data
Lambs infected with RSV had increased body temperatures at days 2 and 3 post infection
regardless of pretreatment group (data not shown). Lambs in both pretreatment groups (PBS
and VEGF) exhibited a moderate cough at days 4 and 5 post infection.
Histology and immunohistochemistry
Histologic lesions of RSV-infected lambs were characterized by multifocal bronchiolitis
with locally extensive alveolar consolidation. Within the lumen of bronchi and bronchioles
were neutrophils and macrophages admixed with cellular debris. Alveoli surrounding
affected bronchi were collapsed and infiltrated by neutrophils with fewer lymphocytes and
plasma cells (Figure 1A). Syncytial cells were present multifocally within bronchiolar
epithelium and within consolidated alveolar parenchyma. RSV antigen was detected in
bronchiolar epithelial cells, syncytial cells, and alveolar macrophages by
immunohistochemistry (Figure 1B). Immunoreactive cells had intense, dark brown,
cytoplasmic staining. At day 6 post infection, RSV-infected lambs pretreated with rhVEGF
had decreased alveolar consolidation, bronchiolitis, and inflammatory cell infiltration as
compared to RSV-infected lambs pretreated with control medium (Figure 1C). There was
reduced RSV antigen at day 6 post infection in rhVEGF-pretreated lambs (Figure 1D).
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Histologic lesion scores were calculated for each treatment group based on alveolar
consolidation and inflammatory cell infiltration (Figure 2).
Real-time qPCR
Effect of rhVEGF on RSV mRNA expression—RSV mRNA levels were measured by
RT-PCR to determine the effect of rhVEGF pretreatment on RSV replication. Lambs
pretreated with rhVEGF had significantly higher RSV mRNA levels at day 4 post infection
than RSV-infected lambs pretreated with PBS. However at day 6, lambs pretreated with
rhVEGF had a marked decrease in RSV mRNA levels as compared to lambs pretreated with
PBS (Figure 3).
Effect of RSV infection and rhVEGF administration on collectin and defensin
gene expression—Surfactant protein and defensins serve important roles in the
pulmonary innate immune response. Expression of surfactant protein-A (SP-A), surfactant
protein-D (SP-D), and β-defensin-1 (SBD-1) mRNAs were measured in order to determine
the effect of rhVEGF pretreatment on the expression of these genes during RSV infection.
rhVEGF induced the expression of SP-A in non–RSV-infected lambs pretreated with VEGF
at days 4 and 6, indicating increased expression was a direct result of rhVEGF
administration (Figure 4). RSV infection induced expression of SP-A at day 4 in both
pretreatment groups. At day 6, RSV-infected lambs pretreated with rhVEGF showed a
marked reduction in SP-A expression compared with lambs pretreated with PBS at the same
time point and expression at day 4. There were no significant changes in SP-D expression
between the groups.
Administration of rhVEGF induced significant increase of SBD-1 mRNA in uninfected
lambs at days 4 and 6, indicating increased expression was a direct result of rhVEGF (Figure
5). RSV infection induced expression of SBD-1 at days 2 and 4 post infection in both
pretreatment groups, showing that increased expression was a result of viral infection. At
day 6, RSV-infected lambs pretreated with rhVEGF had less SBD-1 expression than lambs
pretreated with PBS at day 6 and lower levels than those present at day 4.
Effect of RSV infection and rhVEGF administration on inflammatory mediators
—RSV infection induced the expression of tumor necrosis factor α (TNFα) and
interleukin-8 (IL-8) at day 2 post infection in both pretreatment groups (Figures 6, Figure 7).
Administration of rhVEGF increased TNFα expression at day 4 (Figure 6). There was no
significant alteration in expression of IL-6 and interferon β (IFNβ) by RSV infection or
rhVEGF administration.
Alterations in endogenous VEGF expression due to RSV infection—Expression
of VEGF and VEGF receptor-1 and -2 by lung cells was measured to determine whether
RSV infection and/or the administration of rhVEGF protein altered transcription of
endogenous VEGF and cellular regulation of VEGF receptor-1 and -2. VEGF mRNA was
significantly increased in RSV-infected lambs at day 2 in both pretreatment groups (Figure
8). However, at day 6, levels of VEGF mRNA were markedly decreased in both
pretreatment groups. VEGF receptor transcription was not altered by viral infection or
administration of rhVEGF (data not shown).
Effect of RSV infection and rhVEGF administration on pulmonary cellular
proliferation—VEGF can reduce apoptosis of both endothelial cells and pulmonary
epithelial cells [13, 26]. The effect of VEGF on the growth and proliferation of lung
epithelial cells following injury is not well known. To test this, cellular proliferation was
measured within the lung parenchyma by immunohistochemistry for Ki-67 antigen (Figure
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9). Immunoreactive cells had intense, dark brown nuclear staining. Immunoreactive cells
were present within bronchiolar epithelium and multifocally within the alveolar interstitium.
At day 4, RSV-infected lambs pretreated with rhVEGF had increased cellular proliferation
compared to control (Figure 10). There was no significant difference in RSV-infected lambs
pretreated with PBS at this time point compared to PBS control. At day 6, there were
significantly more Ki-67–immunoreactive cells in RSV-infected lambs pretreated with PBS
compared to lambs pretreated with VEGF. In fact, RSV-infected lambs pretreated with
rhVEGF had no increase in cellular proliferation over control at day 6.
DISCUSSION
VEGF has a vital role in pulmonary development, homeostasis, and disease processes. This
study demonstrates that administration of exogenous rhVEGF prior to RSV infection
decreases the severity of RSV-induced pulmonary lesions at day 6 post infection. In
addition, viral load at 6 days post infection was decreased in lambs pretreated with rhVEGF.
Demonstration of rhVEGF-induced protection against RSV is consistent with our previous
work demonstrating pulmonary protection with a bovine strain of RSV [27]. The
mechanistic basis for decreased RSV pathology is largely unknown; however, we propose
that rhVEGF increases innate immune gene expression by pulmonary epithelial cells and
promotes epithelial cell proliferation leading to enhanced repair. VEGF has numerous other
pulmonary effects that may contribute to alteration of RSV disease, including vascular
leakage and macrophage activation. An unexpected finding was an increase in RSV mRNA
at day 4 post infection in rhVEGF-pretreated lambs. The cause for the higher expression is
unknown but may be related to alteration in cellular responses by rhVEGF. There was no
histologic evidence of increased cellular infiltration or pulmonary pathology that would
indicate increased RSV disease at this time point.
SP-A is a collectin that plays a critical role in pulmonary innate immune responses and also
modulates inflammatory responses. SP-A acts as an opsonin by binding and agglutinating
pathogens and also serves to modulate inflammatory responses in the lung [28]. Exogenous
pulmonary VEGF administration increases SP-A expression and expression of other
surfactant proteins, resulting in pulmonary maturation and making VEGF a possible
therapeutic for pulmonary immaturity [29, 30]. Other routes of VEGF administration also
increase pulmonary surfactant expression. In a preterm rat study, rats given VEGF via intra-
amniotic administration resulted in increased expression of SP-B and SP-D [31]. SPA has
important antiviral functions, including direct virus binding and immune modulation [32].
Human infants with polymorphisms in SP-A show increased susceptibility to RSV infection
[33]. Studies using SP-D knockout mice demonstrate that RSV infection results in impaired
viral clearance with increased infiltration of neutrophils [34]. In this study, lambs pre-treated
with rhVEGF had markedly increased SP-A expression, similar to other studies using
exogenous rhVEGF administration. Lambs infected with RSV alone had increased
expression of SP-A, corresponding to previous studies showing that RSV induces SP-A
expression [18]. Interestingly at day 6 post infection, SP-A expression in RSV-infected
lambs pre-treated with rhVEGF was much lower than animals pretreated with PBS and also
decreased from day 4. Although rhVEGF induces expression of SP-A, there appears to be
modulation of this effect when lambs are infected with RSV. Reduced expression of SP-A at
day 6 in RSV-infected lambs pretreated with VEGF may be secondary to the effects of the
rhVEGF, which may decrease viral load and result in less viral induction of SP-A.
β-Defensins are antimicrobial peptides that have important roles in both the innate and
adaptive immune responses. The antiviral activity of β-defensins include direct antiviral
activity, chemotactic activity for macrophages and immature dendritic cells, and induction
of cytokine signaling by monocytes and epithelial cells [35]. RSV infection induced
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expression of SBD-1 at 2 and 4 days in both pretreatment groups. Pretreatment with
rhVEGF in non–RSV-infected lambs induced expression of SBD-1 at days 4 and 6. The
induction of SBD-1 expression by VEGF has been documented in a previous study showing
that VEGF modulates components of the innate immune response [27]. At day 6, SBD-1
levels in RSV-infected lambs pretreated with VEGF were much lower than lambs pretreated
with PBS. The lower expression level in this group is similar to the decreased expression
observed with SP-A. Again, the cause for the lower expression in this group is unknown, but
may be related to a decrease in viral-induced epithelial responses.
A study investigating VEGF levels in human infants with RSV infection showed up-
regulation of VEGF in the nasal fluid [36]. In many human studies nasal fluid and
bronchoalveolar lavage (BAL) are the only means of measurement, as tissue samples are
often difficult to obtain. In this study, endogenous VEGF expression was increased at day 2
but decreased at day 6. VEGF mRNA was measured in lung homogenates, which may give
an indication of the overall effect of RSV-induced inflammation on VEGF expression.
VEGF is secreted both basolaterally and apically by pulmonary epithelial cells. In addition,
VEGF189 and VEGF206 are bound to the extracellular matrix within the lung tissue and
cleaved to active fragments by plasmin upon extracellular matrix breakdown [4]. Nasal
secretion and BAL measurements provide information as to the expression level in one
location only. An example of the location differences in VEGF levels can be shown in a
study using a neonatal pig lung injury model, which reported decreased VEGF mRNA
expression and protein levels in lung tissue with increased protein levels in the BAL [37].
This poses the question as to the significance of altered expression at various locations and
time points in infection.
Many pulmonary disease processes can result in or be caused by alterations in VEGF
expression. Decreased pulmonary VEGF expression is present in newborns with
bronchopulmonary dysplasia and in acute respiratory distress syndrome [38, 39]. In one
murine model of lipopolysaccharide (LPS)-induced lung, VEGF mRNA and protein
expression were increased following injury with evidence of pulmonary edema [40].
However, in a different model of acute lung injury induced by Pseudomonas aeruginosa,
VEGF mRNA and protein were decreased [41]. In the injury model induced by
Pseudomonas, direct injury to the epithelium may have resulted in decreased expression,
although decreased levels may be an epithelial response to injury. The fact that RSV-
infected lambs in both pretreatment groups showed similar VEGF mRNA expression may
indicate a modulation of epithelial responses rather than epithelial loss leading to decreased
expression.
There is growing evidence that VEGF plays a supportive role in disease processes and that
certain levels are necessary for cellular proliferation and differentiation. In vitro studies
indicate that VEGF has a positive effect on epithelial cellular proliferation and can increase
cell survival via reduction of caspase-3 in apoptosis [42, 43]. At day 4 post infection, there
was enhanced cellular proliferation in RSV-infected lambs pretreated with rhVEGF.
Interestingly, by day 6, proliferation markedly decreased in this group. We proposed that an
increase in cellular proliferation in RSV-infected lambs pretreated with rhVEGF would lead
to enhanced lesion resolution. We initially saw an increase in proliferation at day 4 but not at
day 6. However, lambs pretreated with VEGF had a marked decrease in pulmonary
pathology at day 6, indicating that repair may have occurred at an earlier time point, as may
be suggested by the higher proliferation at day 4. At day 6, RSV-infected lambs pretreated
with PBS had high cellular proliferation, likely due to the severity of RSV infection and the
response to repair the injury.
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Intrapulmonary treatment with rhVEGF at the concentration used in this study resulted in
minimal pulmonary pathology. Administration of rhVEGF has been reported to cause mild
increase in monocyte recruitment early after administration [44]. In a preterm mouse model
of lung prematurity, intratracheal administration of rhVEGF resulted in increased surfactant
protein production with no adverse effects on the lungs [29]. There is a report of pulmonary
hemorrhage and hemosiderosis in a mouse model overexpressing VEGF; however, VEGF
protein was far higher than physiologic levels [45]. The lack of major adverse side effects
with intrapulmonary administration makes VEGF a possible therapeutic candidate.
The effect of rhVEGF pretreatment on viral infection is likely multifactorial, with effects on
cellular proliferation and alteration of epithelial gene expression as described for SP-A and
SBD-1. In addition, VEGF is a monocyte/macrophage chemoattractant [44, 46] via VEGF
receptor-1. Macrophages not only internalize cellular debris but also modulate immune
responses in the lung by secretion of cytokines that are important for activation of CD8+
lymphocytes and antiviral responses [47]. Recruitment of macrophages may aid in the
decreased lesions and virus that were observed in animals pretreated with rhVEGF. A recent
study demonstrated that VEGF serves an immunostimulatory role by increasing the
expression of IL-8, TNFα, and INFγ within 24 hours of administration [48]. In our study,
VEGF increased TNFα with no effect on IL-6 and IL-8.
This study shows that pretreatment with rhVEGF prior to RSV infection decreased viral
mRNA and decreased pulmonary lesion severity at peak infection (day 6) as compared to
RSV animals that did not receive rhVEGF. In addition, rhVEGF increased SP-A and SBD-1
expression, exhibiting regulation of key epithelial innate immune genes. Pretreatment with
rhVEGF altered cellular proliferation in RSV-infected lambs at 4 and 6 days post infection.
There are likely other pulmonary effects induced by administration of rhVEGF in addition to
those investigated here that may provide interesting insight into disease pathogenesis and
further the development of novel therapeutics.
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FIGURE 1.
Photomicrograph of lung from an RSV-infected lamb pretreated with PBS (A) and an RSV-
infected lamb pretreated with VEGF (C). RSV-infected lambs pretreated with PBS had
suppurative bronchiolitis with locally extensive alveolar consolidation and infiltration of
lymphocytes and plasma cells. RSV-infected lambs pretreated with VEGF had decreased
alveolar consolidation, bronchiolitis, and inflammatory cell infiltration. RSV antigen
staining by immunohistochemistry demonstrated multifocal immunoreactive cells within the
bronchiolar epithelium, airway lumen and interstitium (B). Lambs pretreated with VEGF
had decreased antigen at day 6 post infection (D). Bar = 100 μm.
Olivier et al. Page 12
Exp Lung Res. Author manuscript; available in PMC 2011 September 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 2.
Pretreatment with exogenous rhVEGF decreases histologic consolidation score indicating a
decreased in alveolar consolidation and inflammatory cell infiltration (*P < .01).
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FIGURE 3.
At day 2, lambs pretreated with rhVEGF have significantly higher RSV mRNA levels (A).
At day 4 the RSV mRNA levels in the rhVEGF-pretreated lambs are decreasing (B), with
expression levels significantly lower than control-pretreated animals at 6 days post infection
(C) (*P < .05; **P < .01).
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FIGURE 4.
Pretreatment with exogenous rhVEGF and inoculation with RSV alters expression of
surfactant protein A. At day 2, there were no significant differences in SP-A expression (A).
At day 4, administration of rhVEGF increased SP-A expression in non–RSV-infected lambs,
as compared to pretreatment PBS. Inoculation with RSV increased SP-A in both control and
rhVEGF-pretreated groups (B). At day 6, SP-A expression in rhVEGF-pretreated non–RSV-
infected lambs remained increased. SP-A expression was decreased in RSV-infected lambs
that were pretreated with rhVEGF compared to those that were pretreated with PBS (C) (*P
< .05; ** P < .01; ***P < .001).
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FIGURE 5.
Pretreatment with exogenous rhVEGF and inoculation with RSV alters expression levels of
sheep β-defensin-1. At day 2, inoculation with RSV increased SBD-1 levels in both
pretreatment groups; however, SBD-1 expression was higher in animals pretreated with
rhVEGF (A). At day 4, administration of rhVEGF increased SBD-1 expression in non–
RSV-infected lambs, as compared to control. SBD-1 expression in RSV-infected animals
remained increased (B). At day 6, SBD-1 expression in RSV-infected lambs pretreated with
rhVEGF was significantly decreased compared to RSV-infected lambs pretreated with PBS.
SBD-1 expression remained high in non–RSV-infected lambs pretreated with rhVEGF (C)
(*P < .05; **P < .01; ***P < .001).
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FIGURE 6.
Pretreatment with exogenous rhVEGF and inoculation with RSV alters expression levels of
TNFα. At day 2, TNFα expression was significantly increased in RSV-infected lambs in
both pretreatment groups (A). At day 4, TNFα expression increased in non–RSV-infected
lambs pretreated with rhVEGF. Expression decreased from day 2 levels in RSV-infected
lambs, with higher levels in lambs pretreated with rhVEGF (B) (*P < .05; **P < .01; ***P < .
001).
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FIGURE 7.
RSV infection increases expression of IL-8 in both pretreatment groups (*P < .05).
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FIGURE 8.
At day 4, VEGF expression levels are increased in RSV-infected lambs in both pretreatment
groups. At day 6, VEGF expression levels are decreased in RSV-infected animals in both
pretreatment groups (*P < .05; ***P <.001).
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FIGURE 9.
Photomicrograph of immunohistochemical staining for Ki-67 antigen staining to assess
cellular proliferation. Immunoreactive cells are present multifocally within the bronchiolar
epithelium and within the interstitium (A, B). Bar = 100 μm.
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FIGURE 10.
Quantification of Ki-67 immunoreactive cells within lung tissue from lambs in all groups.
At day 4, RSV-infected lambs pretreated with VEGF had increased numbers of Ki-67–
immunoreactive cells compared to VEGF control (A). At day 6, RSV lambs pretreated with
PBS had increased number of KI-67–immunoreactive cells compared to PBS control (B).
RSV-infected lambs pretreated with rhVEGF showed no significant increase in Ki-67
immunoreactivity (*P < .05; ***P < .001).
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TABLE 1
Treatment Groups for Assessing VEGF Pretreatment in RSV Disease
Pretreatment Inoculation
n = 4 (days 2, 4); n = 6 (day 6) PBS Medium
n = 4 (days 2, 4); n = 6 (day 6) PBS RSV
n = 4 (days 2, 4); n = 6 (day 6) VEGF Medium
n = 4 (days 2, 4); n = 6 (day 6) VEGF RSV
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TABLE 2
Primers and Probe Sequences for Ovine Gene Expression Assessed by Real-Time qPCR
RSV Fwd: 5′-GCTCTTAGCAAAGTCAAGTTGAATGA
Rev: 5′-TGCTCCGTTGGATGGTGTATT
Probe: 5′-6FAM-ACACTCAACAAAGATCAACTTCTGTCATCCAGC-TAMRA
SP-A Fwd: 5′-TGACCCTTATGCTCCTCTGGAT
Rev: 5′-GGGCTTCCAAGACAAACTTCCT
Probe: 5′-6FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA
SP-D Fwd: 5′-ACGTTCTGCAGCTGAGAAT
Rev: 5′-TCGGTCATGCTCAGGAAAGC
Probe: 5′-6FAM-TTGACTCAGCTGGCCACAGCCCAGAACA-TAMRA
SBD-1 Fwd: 5′-CCATAGGAATAAAGGCGTCTGTGT
Rev: 5′-CGCGACAGGTGCCAATCT
Probe: 5′-6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRA
IL-8 Fwd: 5′-TTCCAAGCTGGCTGTTGCT
Rev: 5′-TTGACAGAACTGCAGCTTCACA
Probe: 5′-6FAM-CCGCTTTCCTGCTCTCTGCAGCTC-TAMRA
IL-6 Fwd: 5′-GCTGCTCCTGGTGATGACTTC
Rev: 5′-GGTGGTGTCATTTTTGAAATCTTCT
Probe: 5′-6FAM-CTTTCCCTACCCCGGGTCCCCTG-MBGNFQ
TNFα Fwd: 5′-CAACCTGGGACACCCAGAAT
Rev: 5′-TCTCAAGGAACGTTGCGAAGT
Probe: 5′-6FAM-CAAGGGCCAGGGTTCTTACCGGAA-TAMRA
IFNβ Fwd: 5′-TGGTTCTCCTGCTGTGTTTCTC
Rev: 5′-CGTTGTTGGAATCGAAGCAA
Probe: 5′-6FAM-ACCACAGCTCTTTCCAGGAGCTACA-TAMRA
VEGF Fwd: 5′-GCCCACTGAGGAGTTCAACATC
Rev: 5′-TGGCTTTGGTGAGGTTTGATC
Probe: 5′-6FAMCCATGCAGATTATG-MGBNFQ
VEGF Receptor-1 Fwd: 5′-TCAGGTGAGCTTGGACAAAATG
Rev: 5′-CACCGTGCAAGACAGCTTCA
Probe: 5′-6FAM-CTGCGGAAGGAGAG -MGBNFQ
VEGF Receptor-2 Fwd: 5′-CCAGTGGGCTGATGACCAA
Rev: 5′-GCAACAAACGGCTTTTCATGT
Probe: 5′-6FAM-AAGAACAGCACGTTCGTCCGGG-TAMRA
Ubiquitin (ovine) Fwd: 5′-GGTGGCTGTTAATTCTTCAG
Rev: 5′-AAATGGCTAGAGTGCAGAACGAT
OvRPS15 Probe: 5′-6FAM-TTCATAATGCTCAGTGATGG-MGBNFQ
Fwd: 5′-CGAGATGGTGGGCAGCAT
Rev: 5′-GCTTGATTTCCACCTGGTTGA
Probe: 5′-VIC-CCGGCGTCTACAACGGCAAGACC-TAMRA
Note. 6FAM or VIC = 5′ fluorescent reporter dye; TAMRA = fluorescent quencher dye; MGBNFQ = minor groove binding nonfluorescent
quencher.
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